Regenxbio (RGNX) Net Cash Flow (2014 - 2025)
Regenxbio (RGNX) posted quarterly Net Cash Flow of -$24.3 million for Q4 2025, down 2777.23% year-over-year from $909000.0 in Q4 2024, and down 17.25% quarter-over-quarter from -$20.8 million in Q3 2025.
Regenxbio (RGNX) Net Cash Flow (2014 - 2025) Analysis & Trends
Regenxbio's Net Cash Flow history runs 12 years deep, the most recent figure standing at -$24.3 million for Q4 2025.
- In Q4 2025, Net Cash Flow fell 2777.23% year-over-year to -$24.3 million; the TTM figure through Dec 2025 stood at -$23.1 million (down 200.24% YoY), while the FY2025 annual figure was -$23.1 million, down 200.24% from the prior year.
- Net Cash Flow for Q4 2025 stood at -$24.3 million, down from -$20.8 million in the prior quarter.
- The five-year high for Net Cash Flow was $117.5 million in Q4 2021, with the low at -$153.3 million in Q1 2022.
- The 5-year median for Net Cash Flow is -$21.2 million (2022), against an average of -$15.2 million.
- The sharpest annual moves came in 2021 and 2024: Net Cash Flow plunged 45476.7% in 2021, then surged 392.07% in 2024.
- Regenxbio's Net Cash Flow stood at $117.5 million in 2021, then tumbled by 118.37% to -$21.6 million in 2022, then advanced by 13.17% to -$18.7 million in 2023, then jumped by 104.85% to $909000.0 in 2024, then slumped by 2777.23% to -$24.3 million in 2025.
- Business Quant data shows RGNX's Net Cash Flow at -$24.3 million in Q4 2025, -$20.8 million in Q3 2025, and -$50.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24.34 Mn |
| Dec 31, 2025 | -24.34 Mn |
| Sep 30, 2025 | -20.76 Mn |
| Sep 30, 2025 | -20.76 Mn |
| Jun 30, 2025 | -50.55 Mn |
| Jun 30, 2025 | -50.55 Mn |
| Mar 31, 2025 | 72.58 Mn |
| Mar 31, 2025 | 72.58 Mn |
| Dec 31, 2024 | 909,000.00 |
| Dec 31, 2024 | 909,000.00 |
| Sep 30, 2024 | -1.15 Mn |
| Sep 30, 2024 | -1.15 Mn |
| Jun 30, 2024 | -55.21 Mn |
| Jun 30, 2024 | -55.21 Mn |
| Mar 31, 2024 | 78.45 Mn |
| Mar 31, 2024 | 78.45 Mn |
| Dec 31, 2023 | -18.75 Mn |
| Dec 31, 2023 | -18.75 Mn |
| Sep 30, 2023 | -15.56 Mn |
| Sep 30, 2023 | -15.56 Mn |